Zurück zum Zitat Cohen EEW, Cohen E, Soulières D, Le Tourneau C, Dinis J, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness BA, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington K, Harrington KJ, Acosta-Rivera M, Adkins DR, Aghmesheh M, Airoldi M, Aleknavicius E, Al-Farhat Y, Algazi AP, Almokadem S, Alyasova A, Bauman JR, Benasso M, Berrocal A, Bray V, Caponigro F, Castro A, Cescon TP, Chan K, Chaudhry A, Chauffert B, Csoszi T, De Boer JP, Delord J, Dietz A, Dupuis C, Digue L, Erfan J, Escobar Alvarez Y, Evans M, Fidler MJ, Forster MD, Friesland S, Ganti AK, Geoffrois L, Grant C, Gruenwald V, Hoffmann T, Horvai G, Inciura A, Jang R, Jankowska P, Jimeno A, Joseph M, Juarez Ramiro A, Karaszewska B, Kawecki A, Keilholz U, Keller U, Kim S, Kocsis J, Kotecki N, Kozloff MF, Lambea J, Landherr L, Lantsukhay Y, Lazarev SA, Lee LW, Lifirenko ID, Martincic D, Matorin OV, McGrath M, Misiukiewicz K, Morris JC, Mufazalov FF, Niu J, Pamoorthy Srinivasan D, Perez Segura P, Rauch D, Ribeiro ML, Rodriguez C, Rolland F, Russo A, Ruzsa A, Sanches F, Shin S, Shtiveland M, Soulieres D, Specenier P, Szekanecz E, Szota J, van Herpen CML, Velez-Cortes HA (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. https://doi.org/10.1016/s0140-6736(18)31999-8 CrossRefPubMedPubMedCentral
Cohen EEW, Cohen E, Soulières D, Le Tourneau C, Dinis J, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness BA, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington K, Harrington KJ, Acosta-Rivera M, Adkins DR, Aghmesheh M, Airoldi M, Aleknavicius E, Al-Farhat Y, Algazi AP, Almokadem S, Alyasova A, Bauman JR, Benasso M, Berrocal A, Bray V, Caponigro F, Castro A, Cescon TP, Chan K, Chaudhry A, Chauffert B, Csoszi T, De Boer JP, Delord J, Dietz A, Dupuis C, Digue L, Erfan J, Escobar Alvarez Y, Evans M, Fidler MJ, Forster MD, Friesland S, Ganti AK, Geoffrois L, Grant C, Gruenwald V, Hoffmann T, Horvai G, Inciura A, Jang R, Jankowska P, Jimeno A, Joseph M, Juarez Ramiro A, Karaszewska B, Kawecki A, Keilholz U, Keller U, Kim S, Kocsis J, Kotecki N, Kozloff MF, Lambea J, Landherr L, Lantsukhay Y, Lazarev SA, Lee LW, Lifirenko ID, Martincic D, Matorin OV, McGrath M, Misiukiewicz K, Morris JC, Mufazalov FF, Niu J, Pamoorthy Srinivasan D, Perez Segura P, Rauch D, Ribeiro ML, Rodriguez C, Rolland F, Russo A, Ruzsa A, Sanches F, Shin S, Shtiveland M, Soulieres D, Specenier P, Szekanecz E, Szota J, van Herpen CML, Velez-Cortes HA (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet.
https://doi.org/10.1016/s0140-6736(18)31999-8 CrossRefPubMedPubMedCentral